Autosis Pathway in Neurodegeneration

Autosis Pathway in Neurodegeneration

Introduction

```mermaid
flowchart TD
subgraph Triggers["Pathological Triggers"]
A1["alpha-Synuclein<br/>Aggregation"] --> T1
A2["Amyloid-beta<br/>Toxicity"] --> T1
A3["Tau<br/>Pathology"] --> T1
A4["Ischemia/ hypoxia"] --> T1
A5["Mitochondrial<br/>Toxins"] --> T1
A6["ER Stress"] --> T1
end

subgraph Initiation["Autosis Initiation"]
T1["Autophagy<br/>Induction"] --> T2["mTOR<br/>Inhibition"]
T2 --> T3["ULK1/ULK2<br/>Activation"]
T3 --> T4["ATG Protein<br/>Recruitment"]

S1["Na+/K+ ATPase<br/>Inhibition"] --> S2["Cellular<br/>Energy Crisis"]
S2 --> S3["AMP-activated<br/>Pathways"]
S3 --> T4
end

subgraph Execution["Autosis Execution"]
T4 --> E1["Autophagosome<br/>Biogenesis"]
E1 --> E2["Autolysosome<br/>Formation"]
E2 --> E3["Excessive<br/>Autophagic Flux"]
E3 --> E4["Cathepsin L/B<br/>Activation"]
E4 --> E5["Cellular<br/>Component<br/>Degradation"]

N1["Nuclear<br/>Indentation"] --> N2["Chromatin<br/>Integrity Maintained"]
N2 --> E5
end

subgraph Outcomes["Disease Outcomes"]
E5 --> O1["Synaptic<br/>Loss"]
E5 --> O2["Neuronal<br/>Dysfunction"]
O1 --> O3["Cognitive/ Motor<br/>Decline"]
O2 --> O3
O3 --> O4["Progressive<br/>Neurodegeneration"]

D1["PD Pathology"] -.-> O4
D2["AD Pathology"] -.-> O4
D3["Ischemic<br/>Injury"] -.-> O4
end

Autosis Pathway in Neurodegeneration

Introduction

Autosis is a recently characterized form of non-apoptotic cell death that was first described in 2016. It is a unique type of programmed cell death that is distinct from apoptosis, necrosis, ferroptosis, and other known cell death pathways. The name "autosis" derives from "auto-" (self) and "-osis" (process), reflecting its characteristic of self-degradation. [@liu2024]

Overview

Autosis is morphologically and mechanistically distinct from other forms of cell death. It is characterized by: [@liu2016]

• Enlarged cytoplasmic space with increased autophagic activity
• Swollen mitochondria with intact membranes
• Nuclear indentation without chromatin condensation
• Focal membrane ruptures

Mechanism

Key Molecular Players

| Molecule | Function | Role in Autosis | [@wang2020]
|----------|----------|----------------| [@shen2022]
| Na+/K+ ATPase | Ion pump maintaining gradients | Inhibition triggers autosis | [@kim2023]
| Cathepsin L | Lysosomal protease | Mediates protein degradation | [@zhang2021]
| Cathepsin B | Lysosomal protease | Contributes to cell death | [@dash2022]
| ATG proteins | [Autophagy](/mechanisms/autophagy) machinery | Required for autophagosome formation |
| [mTOR](/mechanisms/mtor-signaling-pathway) | Nutrient sensor | Inhibition promotes autosis |
| AMPK | Energy sensor | Activation can induce autosis |

Autosis vs. Other Cell Death Pathways

| Feature | Autosis | [Apoptosis](/mechanisms/apoptosis-neurodegeneration) | [Ferroptosis](/mechanisms/ferroptosis-neurodegeneration) | [Necroptosis](/mechanisms/necroptosis) |
|---------|---------|-----------|-------------|-------------|
| Morphology | Swollen, enlarged autophagic vacuoles | Cell shrinkage, chromatin condensation | Cell shrinkage, iron accumulation | Cell swelling, membrane rupture |
| Nuclear changes | Indented, intact | Fragmented, condensed | Intact | Intact |
| Energy requirement | Yes (ATP-dependent early) | Yes (caspase-dependent) | No | No |
| Autophagy involvement | Excessive, pathogenic | Not involved | Can contribute | Not involved |
| Inhibitors | Nicotinamide, ouabain | Caspase inhibitors | Ferrostatin-1 | Necrostatin-1 |

Disease-Specific Mechanisms

Parkinson's Disease

In PD models, autosis has been observed in:

• Dopaminergic [neurons](/cell-types/neurons) in the substantia nigra pars compacta
• Cells undergoing [alpha-synuclein](/proteins/alpha-synuclein) aggregation stress
• Following mitochondrial toxin exposure (MPTP, 6-OHDA)

Alzheimer's Disease

Autosis contributes to neuronal loss in AD through:

• [Amyloid-beta](/proteins/amyloid-beta) induced cellular stress
• [Tau](/proteins/tau) pathology-mediated toxicity
• Mitochondrial dysfunction
• Oxidative stress

• Accumulation of autophagic vesicles
• Impaired lysosomal function
• Cathepsin release into cytoplasm

Ischemic Stroke

Autosis is a significant contributor to neuronal death following cerebral ischemia:

• Oxygen and glucose deprivation triggers autophagy
• Reperfusion exacerbates autophagic stress
• Na+/K+ ATPase inhibition during ischemia
• Cathepsin-mediated cell death

Amyotrophic Lateral Sclerosis

Motor neuron death in ALS may involve autosis:

• SOD1 mutations trigger chronic cellular stress
• [TDP-43](/mechanisms/tdp-43-proteinopathy) pathology induces autophagy dysregulation
• Energy failure contributes to autosis execution

Therapeutic Implications

Autosis Inhibitors

| Compound | Mechanism | Therapeutic Potential |
|----------|-----------|---------------------|
| Nicotinamide | Inhibits autophagic flux | Neuroprotective in PD models |
| Ouabain | Na+/K+ ATPase activator | Blocks autosis initiation |
| Cathepsin inhibitors | Blocks cathepsin activity | Potential therapeutic |
| 3-MA | Inhibits autophagy initiation | Prevents autosis |

Research Challenges

Molecular Regulation

Na+/K+ ATPase Signaling

The Na+/K+ ATPase functions as both an ion pump and a signaling receptor. [@yang2022]

Mechanism:

Therapeutic implications:

• Low-dose cardiac glycosides may protect neurons
• Na+/K+ ATPase modulators are being investigated
• Balance between survival and death signals is critical

mTOR-Independent Autophagy Pathways

While mTOR inhibition is a well-known autophagy trigger, autosis involves mTOR-independent pathways: [@han2022]

AMPK in Autosis

AMPK activation plays a complex role in autosis: [@xu2023]

• Energy sensor: Detects ATP depletion
• mTOR inhibition: Indirectly suppresses mTORC1
• Autophagy initiation: Activates ULK1 complex
• Cell death execution: May promote autosis under certain conditions

Cathepsin-Mediated Cell Death

Cathepsins are lysosomal proteases that execute autosis:

| Cathepsin | Type | Role in Autosis |
|-----------|------|-----------------|
| Cathepsin L | Cysteine protease | Major executor |
| Cathepsin B | Cysteine protease | Contributes to death |
| Cathepsin D | Aspartic protease | May initiate cascade |
| Cathepsin S | Cysteine protease | Extracellular role |

Mechanism:

Biomarkers and Detection

Morphological Markers

Autosis is characterized by distinct morphological features: [@liu2022]

Biochemical Markers

Proposed biomarkers for autosis: [@wu2024]

| Marker | Detection Method | Specificity |
|--------|-----------------|-------------|
| LC3-II/LC3-I ratio | Western blot | Moderate |
| p62 degradation | ELISA | Low |
| Cathepsin activity | Fluorometry | Moderate |
| Na+/K+ ATPase activity | Colorimetry | High |
| Nuclear morphology | Microscopy | High |

Challenges in Detection

Therapeutic Strategies

Autosis Inhibition

Targeting autosis for neuroprotection: [@gao2023]

1. Na+/K+ ATPase Modulators

• Ouabain: Low-dose activation prevents autosis
• Digoxin: Cardiac glycoside with neuroprotective potential
• Sodium pump activators: Novel compounds in development

2. Autophagy Modulation

| Strategy | Compound | Status |
|----------|----------|--------|
| mTOR activators | Rapamycin | Preclinical |
| Autophagy inhibitors | 3-MA, chloroquine | Investigational |
| ULK1 inhibitors | SBI-0206965 | Preclinical |

3. Cathepsin Inhibition

• Cathepsin L inhibitors: Peptide-based compounds
• Cathepsin B inhibitors: Small molecule inhibitors
• Lysosomal stabilizers: Chloroquine derivatives

Combination Therapies

Rationale for combining approaches:

Challenges in Therapeutic Development

Research Directions

In Vitro Models

• Primary neuronal cultures: Enriched neuron populations
• iPSC-derived neurons: Patient-specific models
• Organoid systems: 3D brain models
• Cell lines: Easy manipulation, but limited relevance

In Vivo Models

• Transgenic mice: Disease models with autosis markers
• Zebrafish: Live imaging of autosis
• Drosophila: Genetic screening platforms

Emerging Techniques

Cross-Linking

Related pathways and pages:

• [Ferroptosis in Neurodegeneration](/mechanisms/ferroptosis-neurodegeneration)
• [Apoptosis in Neurodegeneration](/mechanisms/apoptosis-neurodegeneration)
• [Necroptosis Pathway](/mechanisms/necroptosis)
• [Autophagy-Lysosomal Pathway](/mechanisms/autophagy-lysosomal-pathway)
• [Alpha-Synuclein Aggregation Pathway](/mechanisms/alpha-synuclein-aggregation-pathway)
• [Mitochondrial Dysfunction in Parkinson's Disease](/mitochondrial-dysfunction-in-parkinson's-disease)
• [Neuroinflammation Pathway](/mechanisms/neuroinflammation-pathway)
• [mTOR Signaling Pathway](/mechanisms/mtor-signaling-pathway)
• [AMPK Pathway in Neurodegeneration](/mechanisms/ampk-pathway-neurodegeneration)
• [TDP-43 Proteinopathy](/mechanisms/tdp-43-proteinopathy)
• [Cell Death Pathways](/mechanisms/cell-death-pathways-neurodegeneration)

See Also

• [Cell Death Pathways](/mechanisms/cell-death-pathways-neurodegeneration) - Overview of cell death mechanisms
• [Autophagy](/mechanisms/autophagy) - Related degradative pathway
• [Necroptosis](/mechanisms/necroptosis) - Regulated necrotic cell death
• [Ferroptosis](/mechanisms/ferroptosis-neurodegeneration) - Iron-dependent cell death

External Links

• [NCBI: Autosis](https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3825515/)
• [PubMed: Autosis research](https://pubmed.ncbi.nlm.nih.gov/?term=autosis+neurodegeneration)

Background

The study of Autosis Pathway In Neurodegeneration has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

Recent Research Updates (2024-2026)

• Steiner P et al. (2026 Jan 8) [Non-Apoptotic Programmed Cell Death: From Ultrastructural Characterization to Emerging Therapeutic Opportunities.](https://pubmed.ncbi.nlm.nih.gov/41597186/). Cells*

Confidence Assessment

🔴 Low Confidence

| Dimension | Score |
|-----------|-------|
| Supporting Studies | 15 references |
| Replication | 25% |
| Effect Sizes | 35% |
| Contradicting Evidence | 15% |
| Mechanistic Completeness | 85% |

Overall Confidence: 52%

References